All Blog /
When Should a Growing Biotech Company Bring in a Senior Management Executive?
Leadership

When Should a Growing Biotech Company Bring in a Senior Management Executive?

Illumination Strategy Group logo

Most biotech founders can name the moment they wished they had asked for help sooner. It is usually a financing that took nine months instead of four, a partner call where the data room and the story disagreed, or a board meeting where three directors asked for three different plans. By then, the cost of the gap has already been paid. The harder question comes earlier: when should a growing biotech company bring in a senior management executive, and what should that person actually be hired to do? This article walks through the stage triggers, the warning signs and the practical options, so you can decide on timing while the decision is still cheap.

Why Timing Matters More Than the Title

A growing biotech rarely struggles because nobody is working hard. It struggles because the decisions that shape the next two years get made informally, by whoever happens to be in the room. That risk is sharper than the headline funding numbers suggest. J.P. Morgan's Q3 2026 biopharma licensing and venture report shows venture funding of $23.9 billion across 385 rounds so far this year, yet the third quarter alone brought in $6.7 billion, down from $9.9 billion in the second. Capital is available, but it is not arriving evenly.

The distribution matters as well. Earlier J.P. Morgan analysis, covered by BioSpace, found that venture funds, public investors and large biopharma companies were all steering money toward de-risked assets, which squeezes younger companies hardest. Runway tells a similar story. An EY analysis reported by BioSpace found that around a third of the biotechs it assessed had less than a year of cash at the end of 2025, and only 45 percent of emerging companies had more than two years.

When runway is that thin, a hire who arrives six months late can mean a financing on someone else's terms. That is why timing deserves as much thought as the search itself. A senior management executive adds the most value before the pressure peaks, because strategy is cheapest to change while there is still room to change it.

What a Senior Management Executive Actually Does

Think of a senior management executive as the person who turns a set of capable functions into one company. In a growing biotech, that usually means owning the milestone-based plan, translating between scientists, finance and investors, and making sure commercial questions get asked early enough to change the answer. Titles vary. You might see chief business officer, chief commercial officer, chief operating officer or head of strategy. The title matters less than the scope: this is a cross-functional role with accountability for how the whole company wins, not a specialist seat for one department.

The work also overlaps heavily with what we describe as a strategic leader. If you have read our earlier piece on what a strategic leader does in a pre-revenue biotech, the same four jobs apply here, just with more moving parts. The senior management executive connects science, capital and commercial decisions, owns the value story for each asset, sequences spend against milestones, and leads the outside conversations with investors and partners. As the company grows, they also build the operating rhythm that lets other people make good decisions without waiting for the CEO.

Four Moments That Signal It Is Time

There is no single headcount or funding threshold that tells you when to hire. In practice, the need tends to surface around four moments, and most growing biotechs hit at least two of them within the same year.

Before a Major Financing

A Series A, Series B or crossover round is a test of the whole company, not only the science. Investors will look at the plan, the model, the data room and the team's ability to explain how they fit together. A senior management executive brought in three to six months ahead can pressure-test the milestone logic, tighten the narrative and make sure every document tells the same story. Founders who bring someone in after the first investor meetings go badly are often fixing the pitch while the clock is already running.

Ahead of Indication or Pivotal Trial Decisions

Some decisions are cheap to make and very expensive to reverse. Choosing a lead indication, locking a pivotal trial design or committing to a manufacturing route all fall into that category. These are the moments when commercial and market access thinking should be sitting at the table, asking who the patients are, what the product must show against current care and what a payer will want to see. If those questions are deferred until late-stage data arrives, the trial that would have answered them has usually been designed already.

When Partnering Shifts From Inbound to Intentional

Early partnering conversations tend to be reactive. A larger company shows interest, the team takes the meeting and the agenda follows the other side's questions. Once the company has data worth licensing or a platform worth sharing, that approach stops working. Someone needs to decide what the company actually wants from a partner, which rights it will trade and what a good deal looks like before the first term sheet appears. That judgement sits squarely with a senior management executive.

As the Company Moves From Team to Organisation

Growth brings its own strain. A company that has gone from ten people to forty, opened a second site or started building a commercial function can no longer run on founder intuition alone. Priorities collide, budgets stretch and decisions slow down because nobody is sure who owns them. Hiring a senior management executive at this point is less about adding a smart person and more about installing the structure that lets the team move quickly without losing coherence.

Warning Signs the Gap Is Already Costing You

If none of those moments feels close, it is still worth checking for symptoms, because the gap often announces itself through friction. Board meetings are a good place to start. When decks report activity instead of decisions, and directors ask the same questions meeting after meeting, it usually means nobody owns the answer. The same goes for budget talks that begin from last quarter's spend instead of the next milestone.

The pipeline offers another clue. Programme choices that follow the latest paper or the strongest scientific interest, rather than a view of market size, competing treatments and payer expectations, point to a missing integrator. Fundraising gives the clearest signal of all: pitches that shift from one investor meeting to the next, or a financial model that quietly disagrees with the scientific plan.

A simple test cuts through the noise. Ask three board members, separately, what the company must achieve in the next 18 months and what would make the plan change. If the answers differ, or nobody can name the trigger for a change, you have your answer. It is far cheaper to fix that now than after the next round falls short.

Senior Management Executive or Strategic Leader: Are They the Same?

Not exactly, though the two are close relatives. A strategic leader describes a function: the ownership of the integrated plan that links science, capital, regulatory path and commercial value. A senior management executive describes a seat: a named person with the seniority, mandate and board access to carry that function and several others alongside it. Sometimes the CEO fills both. In other companies, a chief business officer or chief commercial officer does.

The practical question is not who holds the title but who can explain the plan for the next 24 months, defend its assumptions and say what would change it. Scientist founders often do their best work when they pair with someone who owns that plan, so they can stay close to the science. If the honest answer in your company is "the board, collectively", the function is probably unowned, whatever the org chart says.

Full-Time, Stretch or Fractional: Choosing the Route

Once you accept the need, the next question is how to meet it. The right answer depends on stage, runway and how much work there really is.

Stretching an existing executive is the cheapest option. It works when someone on the team has the appetite, the experience and credibility with investors, and when the board gives them a clear mandate and a sponsor. It fails when the person is already carrying a full workload and strategy becomes a side project.

A full-time senior management executive suits companies with a financed plan and enough scope to keep a seasoned leader fully engaged, such as a company approaching clinical data or a major raise. The brief should be specific: milestone ownership, board reporting, partnering responsibility and the budget process, not just a title.

For earlier or leaner companies, the third route is often the best fit. A fractional senior management executive brings experienced judgement to the plan, the investor story and the partnering approach without a full salary or a permanent seat on the executive team. It also gives you time to learn what the role needs to be before committing to a permanent hire. Illumination Strategy provides this through its fractional C-suite leadership service, which places experienced life sciences executives into growing companies for a defined scope and period.

What the First 90 Days Should Deliver

Whichever route you choose, the first three months set the tone. The opening weeks should be about listening and diagnosis: reviewing the asset and its evidence, interviewing board members and key staff, and testing assumptions with a handful of investors or partners. From there, the executive should produce a milestone-based plan with a runway model, a consistent investor and partner narrative, and a short list of decisions that cannot wait.

The early wins come from clarity, not from adding activity. Companies that get this right tend to report faster decisions, easier investor conversations and a board that spends more time advising and less time rebuilding the plan in the meeting. If you are not seeing those changes by the end of the first quarter, the brief probably needs sharpening.

How Illumination Strategy Supports Growing Biotechs

Illumination Strategy works with life sciences companies on exactly this gap. That can mean a short leadership and plan review, or embedded interim leadership across milestone planning, investor positioning and commercial readiness. Our fractional C-suite leadership engagements are designed for founders who need senior judgement now but are not yet ready to build a full executive bench.

If you suspect your company has outgrown informal strategy, start with a conversation about the next 24 months. The answer to who owns that plan will tell you most of what you need to know, and you can explore how fractional leadership works before deciding on the next step.

Frequently Asked Questions

What is a senior management executive in a biotech company?

A senior management executive is a cross-functional leader who owns how the company's science, funding and commercial plans fit together. Typical titles include chief business officer, chief commercial officer or chief operating officer. The role sits close to the CEO and the board, and it is accountable for the milestone plan, investor and partner communication, and early commercial thinking.

When should a growing biotech hire a senior management executive?

Ideally before key decisions become expensive to reverse. That usually means three to six months ahead of a major financing, before indication selection or pivotal trial design, or when partnering starts to move from inbound interest to a deliberate strategy. Companies scaling from a small team to a larger organisation also reach this point.

Is a senior management executive the same as a strategic leader?

They overlap but are not identical. A strategic leader is a function: owning the integrated plan. A senior management executive is a senior seat that carries that function and often more. In some companies the CEO covers both, while in others a business or commercial officer does.

Can a founder CEO cover this role?

Some can, particularly those who have built companies before. Many scientist founders find that deep scientific work and constant outward-facing strategy pull in different directions. Pairing with a business-minded executive often lets the founder stay focused on the science while someone else owns planning, capital and partnerships.

Should we hire full-time or fractional?

Full-time suits companies with the funding, scope and complexity to keep a senior executive fully engaged. Fractional suits earlier or leaner companies that need experienced judgement without a permanent salary. Stage, runway and workload should decide, and a fractional engagement can also act as a bridge to a permanent hire.

What are the signs a biotech needs a senior management executive?

Common signs include board decks that report activity instead of decisions, pipeline choices driven only by scientific interest, investor pitches that change between meetings, and slow decisions with no clear owner. Repeated surprises on timelines or cash are another strong signal that nobody is steering across functions.

How does a senior management executive help with fundraising?

They turn the science into a funding case: the milestone, what it costs, the evidence investors will want and the value created at each step. They also keep the financial model, data room and story consistent, which makes investor conversations sharper and helps diligence move faster.

What should the first 90 days of a new senior management executive look like?

Start with diagnosis: review the asset and evidence, interview the board and key staff, and test assumptions with a few investors or partners. Then deliver a milestone-based plan, a runway model and a clear list of urgent decisions. Early wins come from clarity rather than from adding more activity.

Timothy Glennon, Founder and CEO of Illumination Strategy Group
Timothy Glennon
Founder & CEO — Illumination Strategy Group

With nearly 30 years of life sciences leadership experience, Tim Glennon helps founders, executives, and investors navigate critical growth stages through commercialization strategy, market access, and scalable business planning.

Key Takeaways

  • A senior management executive adds the most value before pressure peaks, while strategy is still cheap to change.
  • Four common triggers: an upcoming financing, indication or pivotal trial decisions, intentional partnering, and growth from team to organisation.
  • Warning signs include board decks that report activity rather than decisions and pitches that change between meetings.
  • Choose between stretching an existing executive, hiring full-time, or bringing in fractional leadership based on stage, runway and workload.
  • The first 90 days should deliver a milestone plan, a runway model and a short list of urgent decisions.

Senior Commercial Perspectives, In Your Inbox

Get ISG’s perspectives on life sciences commercial strategy — capital formation, launch, business development, and the leadership decisions that define enterprise value.

More Insights

See how we’ve helped organizations achieve measurable commercialization success across industries.

Illumination Strategy Group logo
Leadership

Wondering when to bring in a senior management executive? Learn the signs, stage triggers and options for growing biotechs from Illumination Strategy.

Illumination Strategy Group logo
Leadership

Discover what makes a strategic leader effective in a growing biotech, from decision-making to commercial execution. Insights from Illumination Strategy.

Medical team in a leadership meeting around a conference table
Leadership

What a strategic leader does in a pre-revenue biotech, and the warning signs your company lacks one. Guidance from Illumination Strategy for founders.

Commercial leaders building a sales and marketing organization
Leadership

Practical lessons from scaling a commercial organization from inception through first-in-class launch — function by function, hire by hire.